In breast cancer patients, serum levels of IL-6 and soluble IL-6 receptor (sIL-6R) are significantly higher in those with CIPN compared to those without symptoms, suggesting that persistent CIPN and reduced quality of life may be linked to increased levels of the inflammatory mediator IL-6 and its soluble receptor (76). This evidence concerns the gene IL6 and breast carcinoma.